Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Debio 0123 in Advanced Solid Tumors
NCT05109975Phase 1Terminated
- Sponsor
- Debiopharm
- Start
- Nov 2021
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of zedoresertib in solid tumor, uterine serous carcinoma (USC) and epithelial ovarian cancer (EOC) (2 arms), sponsored by Debiopharm. Primary endpoints: Maximum Tolerated Dose at 3 weeks, Recommended Phase 2 Dose at 3 weeks and 4 more. Started Nov 2021; status: terminated.
02
Drugs
zedoresertib
03
Conditions
solid tumoruterine serous carcinoma (USC)epithelial ovarian cancer (EOC)
Beyond the preview
Go deeper on NCT05109975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05109975.